ArticleFrontiers in pharmacology2026
Exploring the mechanism of action of tripterygium glycosides tablets in the treatment of rheumatoid arthritis based on the Lnc-ENST00000602558/IGF1 signaling pathway.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Rheumatoid arthritis (RA) is a chronic inflammatory joint disease and the leading cause of joint-related limb disability. Traditional Chinese Medicine (TCM) offers certain advantages in RA treatment, and Tripterygium preparations are widely used due to their significant clinical efficacy. This study aimed to investigate the mechanism of action of Tripterygium Glycosides Tablets (TG) in the treatment of RA through Methods: A collagen-induced arthritis (CIA) rat model was established, and the rats received oral administration of the corresponding drugs or distilled water for 4 weeks. The therapeutic effect and mechanism of TG on CIA rats were evaluated by comparing joint swelling severity, radiographic changes in the synovium, and alterations in the JAK/STAT signaling pathway and related inflammatory factors. Further Results: TG significantly improved joint swelling, bone and cartilage destruction in CIA rats, reduced synovial tissue hyperplasia, inhibited the JAK/STAT pathway and IGF1 in the rat joint synovium, lowered serum levels of the inflammatory factors TNF-α and IL-1β, alleviated joint damage, and delayed disease progression. Conclusion: TG may regulate the JAK/STAT pathway via the Lnc-ENST00000602558/IGF1 axis, thereby inhibiting the inflammatory response, mitigating bone and cartilage destruction, and delaying disease progression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.